Multiple Protein Analysis of Formalin-fixed and Paraffin-embedded Tissue Samples with Reverse phase Protein Arrays

Reverse-phase protein arrays (RPPAs) have become an important tool for the sensitive and high-throughput detection of proteins from minute amounts of lysates from cell lines and cryopreserved tissue. The current standard method for tissue preservation in almost all hospitals worldwide is formalin fixation and paraffin embedding, and it would be highly desirable if RPPA could also be applied to formalin-fixed and paraffin embedded (FFPE) tissue. We investigated whether the analysis of FFPE tissue lysates with RPPA would result in biologically meaningful data in two independent studies. In the first study on breast cancer samples, we assessed whether a human epidermal growth factor receptor (HER) 2 score based on immunohistochemistry (IHC) could be reproduced with RPPA. The results showed very good concordance between the IHC and RPPA classifications of HER2 expression. In the second study, we profiled FFPE tumor specimens from patients with adenocarcinoma and squamous cell carcinoma in order to find new markers for differentiating these two subtypes of non-small cell lung cancer. p21-activated kinase 2 could be identified as a new differentiation marker for squamous cell carcinoma. Overall, the results demonstrate the technical feasibility and the merits of RPPA for protein expression profiling in FFPE tissue lysates.

[1]  Jinha M. Park,et al.  Diagnostic Evaluation of HER-2 as a Molecular Target: An Assessment of Accuracy and Reproducibility of Laboratory Testing in Large, Prospective, Randomized Clinical Trials , 2005, Clinical Cancer Research.

[2]  R. Jakobi,et al.  p21-activated Protein Kinase γ-PAK Suppresses Programmed Cell Death of BALB3T3 Fibroblasts* , 2001, The Journal of Biological Chemistry.

[3]  M. A. Bopp,et al.  Zeptosens' protein microarrays: A novel high performance microarray platform for low abundance protein analysis , 2002, Proteomics.

[4]  K. Becker,et al.  Deciphering signaling pathways in clinical tissues for personalized medicine using protein microarrays , 2010, Journal of cellular physiology.

[5]  Markus Ehrat,et al.  Antibody‐based proteomics , 2009, The FEBS journal.

[6]  S. Hewitt,et al.  A well‐based reverse‐phase protein array applicable to extracts from formalin‐fixed paraffin‐embedded tissue , 2008, Proteomics. Clinical applications.

[7]  Marta Cuadros,et al.  Systematic Review of HER2 Breast Cancer Testing , 2009, Applied immunohistochemistry & molecular morphology : AIMM.

[8]  J. Deddens,et al.  Pak-1 Expression Increases with Progression of Colorectal Carcinomas to Metastasis , 2004, Clinical Cancer Research.

[9]  J. Myles,et al.  Fluorescence In Situ Hybridization (FISH) as Primary Methodology for the Assessment of HER2 Status in Adenocarcinoma of the Breast: A Single Institution Experience , 2007, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[10]  M. Monden,et al.  Extraction and Analysis of Diagnostically Useful Proteins from Formalin-fixed, Paraffin-embedded Tissue Sections , 1998, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[11]  Nandini Dendukuri,et al.  Testing for HER2-positive breast cancer: a systematic review and cost-effectiveness analysis , 2007, Canadian Medical Association Journal.

[12]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[13]  G M Bokoch,et al.  Membrane and morphological changes in apoptotic cells regulated by caspase-mediated activation of PAK2. , 1997, Science.

[14]  J. Nährig,et al.  Quantitative protein analysis from formalin‐fixed tissues: implications for translational clinical research and nanoscale molecular diagnosis , 2007, The Journal of pathology.

[15]  P. Selby,et al.  Development and validation of a novel protein extraction methodology for quantitation of protein expression in formalin‐fixed paraffin‐embedded tissues using western blotting , 2009, The Journal of pathology.

[16]  E. Kay,et al.  C-erbB-2 immunostaining: problems with interpretation. , 1994, Journal of clinical pathology.

[17]  M. Owens,et al.  HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. , 2004, Clinical breast cancer.

[18]  K. Jirström,et al.  Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients. , 2006, Journal of the National Cancer Institute.

[19]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2006, Archives of pathology & laboratory medicine.

[20]  E. Petricoin,et al.  Molecular Analysis of HER2 Signaling in Human Breast Cancer by Functional Protein Pathway Activation Mapping , 2012, Clinical Cancer Research.

[21]  Rakesh Kumar,et al.  Emerging functions of p21‐activated kinases in human cancer cells , 2002, Journal of cellular physiology.

[22]  J. McCubrey,et al.  EGFR family signaling and its association with breast cancer development and resistance to chemotherapy (Review). , 2003, International journal of oncology.

[23]  D. Sloane,et al.  An Introduction to Categorical Data Analysis , 1996 .

[24]  A. Tanca,et al.  Generation of high‐quality protein extracts from formalin‐fixed, paraffin‐embedded tissues , 2009, Proteomics.

[25]  A. Harris,et al.  Targeting p21-activated kinase 1 (PAK1) to induce apoptosis of tumor cells , 2011, Proceedings of the National Academy of Sciences.

[26]  Daniel F Hayes,et al.  c-erbB-2 in breast cancer: development of a clinically useful marker. , 2002, Seminars in oncology.

[27]  R. Jakobi,et al.  p21-activated protein kinase gamma-PAK suppresses programmed cell death of BALB3T3 fibroblasts. , 2001, The Journal of biological chemistry.

[28]  William N. Venables,et al.  Modern Applied Statistics with S , 2010 .

[29]  B. Balgley,et al.  Protein Extraction from Formalin-fixed, Paraffin-embedded Tissue Sections: Quality Evaluation by Mass Spectrometry , 2006, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[30]  E. Perez,et al.  HER2-Positive Breast Cancer: Current Treatment Strategies , 2008, Cancer investigation.

[31]  W. Fraser Symmans,et al.  Standardizing Slide-Based Assays in Breast Cancer: Hormone Receptors, HER2, and Sentinel Lymph Nodes , 2007, Clinical Cancer Research.

[32]  M. Bui,et al.  Prognostic and predictive value of HER2/neu oncogene in breast cancer , 2002, Microscopy research and technique.

[33]  B. Ljung,et al.  HER2 testing in breast cancer: NCCN Task Force report and recommendations. , 2006, Journal of the National Comprehensive Cancer Network : JNCCN.

[34]  S. Schnitt,et al.  Current status of HER2 testing: caught between a rock and a hard place. , 2001, American journal of clinical pathology.

[35]  HER-2 testing in breast cancer using immunohistochemical analysis and fluorescence in situ hybridization: a single-institution experience of 2,279 cases and comparison of dual-color and single-color scoring. , 2004, American journal of clinical pathology.

[36]  John J Spinelli,et al.  HER-2/neu in Breast Cancer: Interobserver Variability and Performance of Immunohistochemistry with 4 Antibodies Compared with Fluorescent In Situ Hybridization , 2001, Modern Pathology.

[37]  A. Agresti.  An introduction to categorical data analysis , 1997 .

[38]  L. Liotta,et al.  Monitoring Proteins and Protein Networks Using Reverse Phase Protein Arrays , 2010, Disease markers.

[39]  H. Höfler,et al.  Guided protein extraction from formalin‐fixed tissues for quantitative multiplex analysis avoids detrimental effects of histological stains , 2008, Proteomics. Clinical applications.

[40]  D. Hicks,et al.  Trastuzumab as adjuvant therapy for early breast cancer: the importance of accurate human epidermal growth factor receptor 2 testing. , 2009, Archives of pathology & laboratory medicine.

[41]  C. C. McCarthy,et al.  Caspase-activated PAK-2 Is Regulated by Subcellular Targeting and Proteasomal Degradation* , 2003, Journal of Biological Chemistry.

[42]  C. Gallagher.  Extending the Linear Model With R: Generalized Linear, Mixed Effects and Nonparametric Regression Models , 2007 .

[43]  S. Seelig.  Fluorescence in situ hybridization versus immunohistochemistry: importance of clinical outcome. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  Sanjay Mukhopadhyay,et al.  Subclassification of Non-small Cell Lung Carcinomas Lacking Morphologic Differentiation on Biopsy Specimens: Utility of an Immunohistochemical Panel Containing TTF-1, Napsin A, p63, and CK5/6 , 2011, The American journal of surgical pathology.

[45]  L. Liotta,et al.  A nondestructive molecule extraction method allowing morphological and molecular analyses using a single tissue section , 2005, Laboratory Investigation.

[46]  A. Hopkins.  Network pharmacology: the next paradigm in drug discovery. , 2008, Nature chemical biology.